biogen

  1. lgelb

    Biogen picks up Ionis SOD1 treatment option

    This is important not just for advancing SOD1 tx, but establishing another case where a smaller firm (where a lot of ALS work is being done) has successfully handed off a therapy to a larger firm. This helps incentivize ALS research. ---- [Adapted from Seeking Alpha] Having seen positive...
  2. lgelb

    Biogen acquires two ALS candidates

    "Today Biogen announced it has acquired ALG-801 (Phase 1a) and ALG-802 (preclinical) from AliveGen, Inc. ALG-801 (now known as BIIB110) and ALG-802 represent novel ways of targeting the myostatin pathway, which is one of the most thoroughly studied approaches for muscle enhancement. BIIB110...
  3. lgelb

    ALS survey

    I'm no longer eligible, so don't know how good a study it is, but in case you're not on the mailing list: This initiative, titled IMPACT-ALS (Investigating and Measuring Patient And Caregiver Trends about ALS), is a collaboration with three industry partners (Biogen, Ionis, and Cytokinetics)...
  4. D

    Familial ALS research

    We have a long history of ALS in our family, dating back at least 4 generations (losses include my mother, grandfather, great grandfather, and many distant relatives). I was surprised to know that my family didn't have much documentation or research to pass along to me when I was diagnosed. My...
  5. Sequoia

    Biogen quits development of dexpramipexole for ALS

    Biogen Idec Inc. BIIB -3.45% said its Phase 3 clinical trial for an ALS treatment didn't meet its primary goals, causing the biopharmaceutical firm to discontinue development of the drug for the disease. Shares sank 5.9% to $141.21 premarket. As of Wednesday's close, the stock was down 1.9%...
  6. E

    Biogen quits development of dexpramipexole for ALS

    terrible news but not very surprising. Rob Tyson when he did his analysis a few months back of PLM data told everyone that Dexipramipexole showed little if any efficacy. He is the same guy that reported data for NP 001 showing it to be very successful. There are other off label and phase 2...
  7. Sequoia

    Tuned down for receiving dex.

    I AM SO ANGRY! i RECEIVED THIS LETTER FROM THE DEX TRIAL COORDINATOR: Hi Sharon, Hope all is well with you. I believe the home nurse will be visiting you this Saturday, Sept 22nd for the end of study visit for the Biogen study. Unfortunately this will be your final visit for the study. I...
  8. Sequoia

    Let's all ask Biogen to Treat Us Now!

    hello every body! I am amazed that the new treatment Dex. has been around for over 14 years! From phase I to now phase III which won't finish until next December. I am losing muscle in legs, arms, hands, effecting my swallowing, speech, and now breathing. We know how this goes, and it goes...
  9. A

    More MDA/ALS Research News

    December 28, 2011 ALS TDI Teams with Two Biotechs to Develop Therapy The MDA-supported ALS Therapy Development Institute (ALS TDI) will collaborate with Biogen Idec and UCB to test CDP7657, a compound that modulates the immune system Article Highlights: • CDP7657 is an antibody fragment that...
  10. I

    Together we stand tall

    Together we stand tall. Mail text below to Knopp, biogen (every office worlwide), family and friends evererybody send those mails, because most off pals cant wait 3 years till it's for sale. Compassionate Use Drug Availability for ALS Patients Time to wade into the water on a controversial...
Back
Top